share_log

高盛：维持海吉亚医疗中性评级 目标价升至60港元

Goldman Sachs Group: maintain the target price of Hagia Medical Neutral rating to HK $60

新浪港股 ·  Sep 6, 2022 07:35
Hot column The capital flow of the market center of the optional stock data center flows to the simulated transaction.
Client

Goldman Sachs Group released a research report saying that maintaining Hagia Medical Care(06078) "neutral" rating, the target price has been raised from HK $57 to HK $60. In the first half of this year, revenue increased by 64% compared with the same period last year, IFRS net profit increased by 13%, and non-IFRS net profit increased by 47%.

The bank believes that the better-than-expected revenue is mainly due to faster-than-expected growth of the two hospitals acquired last year, while stronger-than-expected profits reflect better control of operating expenses, partly offset by relatively large one-time foreign exchange losses. As a result, the bank raised its full-year revenue forecast by 1 per cent and its non-IFRS net profit forecast by 7 per cent, while the IFRS net profit forecast was cut by 6 per cent. The bank estimates that the company's revenue in the second half of this year and the whole year rose 34 per cent and 46 per cent compared with the same period last year, and expects full-year net profit under international financial standards and non-international financial standards to be 560 million and 665 million yuan respectively.

Responsible editor: Li Shuangshuang

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment